MTM1

Across TCGA pan-cancer cohorts, MTM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTM1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTM1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MTM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where MTM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.642	0.354	.001	54	view →
CCRCC	DFS	Quartile	All	1.000	0.322	.001	36	view →
UCEC	DFS	Quartile	All	0.958	0.779	.043	4	view →
GBM	OS	Median	All	0.295	0.462	.026	4	view →
LUAD	OS	Quartile	III,IV	0.821	0.383	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTM1–PDAC (OS)

Open the PDAC breakdown →